A new modeling study reveals that lisocabtagene maraleucel (liso-cel) offers better survival and quality of life for follicular lymphoma patients who have received at least two prior therapies, with fewer time toxicity challenges compared to mosunetuzumab.
SAN DIEGO — Despite its significantly higher acquisition costs, lisocabtagene maraleucel (liso-cel, Breyanzi) demonstrated better survival and quality of life as well as fewer time toxicity challenges than mosunetuzumab in patients with follicular lymphoma who have received at least two prior lines of therapy, according to a modeling study presented at the .
Liso-cel, a CD19-directed chimeric antigen receptor T-cell product, and mosunetuzumab, a CD20/CD3 bispecific antibody, are used to treat patients with relapsed/refractory follicular lymphoma. Assessments of treatment benefits largely focus on economic, clinical, and quality-of-life outcomes; however, patients' time investment (time toxicity) is often overlooked. To assess the costs and time associated with liso-cel and mosunetuzumab, researchers developed a model to calculate total costs, outcomes, and time toxicity for patients receiving these therapies for follicular lymphoma after at least two lines of therapy. Researchers designed a health economic model to estimate progression-free survival (PFS). Time toxicity — defined as time spent receiving medical care — included every instance of healthcare resource utilization, such as inpatient or outpatient visits, laboratory tests, and emergency care. Pre- and posttreatment costs, long-term monitoring, progression-related costs, adverse event rates, productivity loss, and indirect costs (such as lost wages and travel costs for outpatient visits or hospitalizations) were also analyzed. The model assumed one infusion of liso-cel and eight infusions of mosunetuzumab. Time toxicity, clinical, and economic outcomes were evaluated across multiple time horizons (1-5 years, 10 years, and across patients' lifetime), with 5 years as the base case reported in this study. Over 5 years, patients treated with liso-cel demonstrated a higher median PFS than those treated with mosunetuzumab — 51 months vs 18 months — based on the mode
Follicular Lymphoma Liso-Cel Mosunetuzumab Time Toxicity Survival Rate
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Immediate Surgery Significantly Improves Long-Term Survival in Older Breast Cancer Patients, Meta-Analysis ShowsMeta-analysis of three trials found that immediate breast surgery in women over 70 cut breast cancer death rates in half after 5 years compared with delayed surgery.
Read more »
Innovative Proton Beam Therapy Shows Promise for Older Glioblastoma PatientsA phase 2 study by Mayo Clinic researchers shows that short-course hypofractionated proton beam therapy, combined with advanced imaging, may improve overall survival in older patients with newly diagnosed glioblastoma while maintaining quality of life. The study found a 56% survival rate after 12 months and a median overall survival of 13.1 months, significantly exceeding historical data for this patient population.
Read more »
The Most Dangerous Reality TV Shows: Dancing on Ice, The Jump and MoreReality TV can be an extreme sport at times between survival shows like ‘Naked and Afraid’ and competition shows like ‘Dancing on Ice’
Read more »
Pancreatic cancer patient survival doubled with high dose of common vitamin, study findsResearchers at the University of Iowa found that adding high-dose IV vitamin C to chemotherapy helped increase survival in pancreatic cancer patients. Study author Dr. Cullen and oncologists discuss.
Read more »
High Doses of Vitamin C May Double Survival Rates for Pancreatic Cancer PatientsThe University of Iowa Health Care Carver College of Medicine has published results from a phase 2 trial showing that adding high-dose vitamin C to chemotherapy treatments can significantly increase survival rates for pancreatic cancer patients. Researchers reported doubling the overall survival time from eight to 16 months, and extending progression-free survival from four to six months. The study, published in Redox Biology, is a culmination of 20 years of research on vitamin C.
Read more »
Lake Superior Could Be Devastated by 'Wall of Water'A reservoir with waste from a Minnesota mine is at the heart of a legal battle. The consequences for Lake Superior could be huge.
Read more »